Exact Sciences Revenue 2010-2024 | EXAS

Exact Sciences revenue for the twelve months ending September 30, 2024 was $2.692B, a 11.91% increase year-over-year.

  • Exact Sciences annual revenue for 2023 was $2.5B, a 19.93% increase from 2022.
  • Exact Sciences annual revenue for 2022 was $2.084B, a 17.95% increase from 2021.
  • Exact Sciences annual revenue for 2021 was $1.767B, a 18.49% increase from 2020.

Exact Sciences Revenue 2010-2024 | EXAS

  • Exact Sciences annual revenue for 2023 was $2.5B, a 19.93% increase from 2022.
  • Exact Sciences annual revenue for 2022 was $2.084B, a 17.95% increase from 2021.
  • Exact Sciences annual revenue for 2021 was $1.767B, a 18.49% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.6B
Vertex Pharmaceuticals (VRTX)$129B
Bristol Myers Squibb (BMY)$113.5B
Gilead Sciences (GILD)$112.3B
CSL (CSLLY)$91.7B
Regeneron Pharmaceuticals (REGN)$91.1B
GSK (GSK)$76.7B
Argenex SE (ARGX)$36B
Alnylam Pharmaceuticals (ALNY)$34.2B
BioNTech SE (BNTX)$26.4B
Biogen (BIIB)$25.8B
Illumina (ILMN)$24.7B
Moderna (MRNA)$20.5B
BeiGene (BGNE)$20.3B
Genmab (GMAB)$15.1B
Incyte (INCY)$14.9B
BioMarin Pharmaceutical (BMRN)$12.6B
Insmed (INSM)$12.4B
Bio-Techne Corp (TECH)$12.3B
Vaxcyte (PCVX)$12B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10B
Exelixis (EXEL)$9.9B
Revolution Medicines (RVMD)$9.5B
Intra-Cellular Therapies (ITCI)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8.2B
Legend Biotech (LEGN)$8.1B
Ascendis Pharma (ASND)$7.8B